{
    "id": 1402,
    "fullName": "MDM2 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MDM2 amp indicates an increased number of copies of the MDM2 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4193,
        "geneSymbol": "MDM2",
        "terms": [
            "MDM2",
            "ACTFS",
            "hdm2",
            "HDMX",
            "LSKB"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "05/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11639,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, 100% (5/5) of solid tumor patients harboring MDM2 amplification experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9987,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DS-3032b demonstrated safety and some preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplification, 1 with liposarcoma and 1 with carcinoid tumor ((J Clin Oncol 34, 2016 (suppl; abstr 2581)).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 2079,
                "therapyName": "DS-3032b",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7837,
                    "pubMedId": null,
                    "title": "A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
                    "url": "http://meetinglibrary.asco.org/content/166204-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16860,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with an unspecified MDM2 inhibitor resulted in clinical efficacy in six patients with liposarcoma harboring MDM2 amplification, including three patients with a partial response and two patients with stable disease for 15.7 months and 4.7 months (PMID: 30237864).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 8207,
                "therapyName": "unspecified MDM2 inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12778,
                    "pubMedId": 30237864,
                    "title": "Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30237864"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11627,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with triple-receptor negative breast cancer that harbored MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in new chest wall metastasis and a 55% increase of existing lung metastasis size 1.5 months after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9988,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DS-3032b demonstrated safety and some preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplification, 1 with liposarcoma and 1 with carcinoid tumor ((J Clin Oncol 34, 2016 (suppl; abstr 2581)).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 2079,
                "therapyName": "DS-3032b",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7837,
                    "pubMedId": null,
                    "title": "A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
                    "url": "http://meetinglibrary.asco.org/content/166204-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11628,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with endometrial stromal sarcoma that harbored MDM2 amplification quickly progressed after receiving Opdivo (nivolumab), resulted in new abdominal metastasis and a 242% increase of existing liver metastasis size within 1.5 months of treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 4226,
                "name": "endometrial stromal sarcoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13986,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in liposarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11624,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic bladder cancer that harbored MDM2 amplification and other mutations quickly progressed after receiving Tecentriq (atezolizumab), resulting in new liver metastasis and a 258% increase of existing liver metastasis size 1.9 months after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited tumor growth in osteosarcoma cell line xenograft models with wild-type TP53 and MDM2 amplification (PMID: 25567130, PMID: 24967612).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 835,
                    "pubMedId": 24967612,
                    "title": "Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24967612"
                },
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma multiforme (GBM) cell lines with amplification of MDM2 and wild-type TP53 demonstrated sensitivity to RG7112 in culture, resulting in decreased viability and restoration of Tp53 signaling, and treatment with RG7112 resulted in growth inhibition in MDM2-amplified TP53 wild-type GBM cell line xenograft models (PMID: 26482041).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2076,
                "therapyName": "RG7112",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7072,
                    "pubMedId": 26482041,
                    "title": "Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Adriamycin (doxorubicin) inhibited tumor growth and induced tumor regression in an MDM2-amplifed TP53 wild-type osteosarcoma cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 4636,
                "therapyName": "Doxorubicin + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18037,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 62.5% (10/16) of patients with TP53 wild-type, MDM2 amplified solid tumors other than liposarcoma, glioblastoma, and breast cancer, with a median duration of 3.3 months, and a patient with squamous cell carcinoma achieved unconfirmed partial response per central evaluation (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18036,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial,  KRT-232 (AMG 232) demonstrated acceptable safety, and resulted in stable disease in 60% (6/10) of patients with TP53 wild-type, MDM2 amplified glioblastoma, with a median duration of 1.8 months (PMID: 31359240; NCT01723020).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15968,
                    "pubMedId": 31359240,
                    "title": "Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31359240"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1788,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type, MDM2 amplified osteosarcoma in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9025,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 decreased viability and induced cell cycle arrest in MDM2-amplified dedifferentiated liposarcoma cell lines with wild-type TP53 in culture, and induced TP53 pathway activation and tumor regression in xenograft models (PMID: 26475335).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 3382,
                "name": "liposarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6874,
                    "pubMedId": 26475335,
                    "title": "SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26475335"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) treatment resulted in reduced tumor size and improved clinical performance for 11 months in a patient with triple-receptor negative breast cancer which harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) and Xeloda (capecitabine) combination treatment resulted in continued clinical performance improvement following progression on Neratinib (HKI-272) monotherapy in a patient with triple-receptor negative breast cancer that harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification, and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4735,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK, wild-type TP53, and MDM2 amplification (PMID: 26438783).",
            "molecularProfile": {
                "id": 18882,
                "profileName": "ALK wild-type MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 3601,
                "therapyName": "Crizotinib + Cyclophosphamide + Topotecan",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4681,
                    "pubMedId": 26438783,
                    "title": "Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438783"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11630,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma that harbored KIF5B-RET fusion and MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in a 135% increase of existing lung metastasis size 9 days after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 28173,
                "profileName": "KIF5B - RET MDM2 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma that harbored CDK4 amplification and MDM2 amplification quickly progressed after receiving Keytruda (pembrolizumab), resulted in new brain metastasis and clinical progression 1.5 months after treatment (PMID: 28351930).",
            "molecularProfile": {
                "id": 28174,
                "profileName": "CDK4 amp MDM2 amp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13987,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in leiomyosarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053).",
            "molecularProfile": {
                "id": 29900,
                "profileName": "MDM2 amp TP53 loss"
            },
            "therapy": {
                "id": 2113,
                "therapyName": "GDC-0575 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1967,
                "name": "leiomyosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11402,
                    "pubMedId": 29409053,
                    "title": "CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14391,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a glioblastoma patient harboring amplifications in CD274, PDCD1LG2, JAK2, MET, and MDM2 was sensitive to the combined therapy of Opdivo (nivolumab) and Cometriq (cabozantinib), demonstrating a partial response at four weeks (PMID: 29902298).",
            "molecularProfile": {
                "id": 29995,
                "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 2067,
                "therapyName": "Cabozantinib + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15032,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with gastroesophageal junction adenocarcinoma with Mdm2 amplification, low tumor mutational burden, and MSI stable, had hyperprogression after treatment with Opdivo (nivolumab) (PMID: 30148248).",
            "molecularProfile": {
                "id": 30606,
                "profileName": "MDM2 amp MSI low TMB low"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12407,
                    "pubMedId": 30148248,
                    "title": "Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30148248"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1425,
            "profileName": "MDM2 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 143,
                    "name": "MDM2 Inhibitor",
                    "profileName": "MDM2 amp"
                }
            ]
        },
        {
            "id": 2169,
            "profileName": "MDM2 amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14286,
            "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18882,
            "profileName": "ALK wild-type MDM2 amp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26181,
            "profileName": "BRAF V600E MDM2 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28173,
            "profileName": "KIF5B - RET MDM2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28174,
            "profileName": "CDK4 amp MDM2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29900,
            "profileName": "MDM2 amp TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29995,
            "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30606,
            "profileName": "MDM2 amp MSI low TMB low",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}